Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)), specifically Group VIIA PLA(2), is a member of the
phospholipase A(2) superfamily and is found mainly associated with
LDL and HDL in human plasma.
Lp-PLA(2) is considered as a risk factor, a potential
biomarker, a target for
therapy in the treatment of
cardiovascular disease, and evidence suggests that the level of
Lp-PLA(2) in plasma is associated with the risk of future cardiovascular and
stroke events. The differential location of the
enzyme in
LDL/
HDL lipoproteins has been suggested to affect
Lp-PLA(2) function and/or its physiological role and an abnormal distribution of the
enzyme may correlate with diseases. Although a mutagenesis study suggested that a surface helix (residues 362-369) mediates the association between
Lp-PLA(2) and HDL, the molecular details and mechanism of association has remained unknown. We have now employed
hydrogen deuterium exchange mass spectrometry to characterize the interaction between recombinant human
Lp-PLA(2) and human HDL. We have found that specific residues 113-120, 192-204, and 360-368 likely mediate HDL binding. In a previous study, we showed that residues 113-120 are important for Lp-PLA(2)-liposome interactions. We now find that residues 192-204 show a decreased deuteration level when
Lp-PLA(2) is exposed to
apoA-I, but not
apoA-II, the most abundant
apoproteins in HDL, and additionally, residues 360-368 are only affected by HDL.The results suggest that
apoA-I and
phospholipid membranes play crucial roles in
Lp-PLA(2) localization to HDL.